Skip to Content

Awards & Funding




2020: Winner, Paul Dudley White International Scholar Award, awarded to the highest-ranked abstract from Australia, Basic Cardiovascular Science Scientific Sessions (American Heart Association)

2019: Inaugural 40 under 40: most influential Asian-Australian Awards (Science and Medicine sector).

2018: Winner, Science Meets Business, Medicine Soapbox

2018: Winner, Best Publication Awards (Alfred Research Alliance)

2017: Winner, International Society of Heart Research Early Career Investigator Award

2016: Winner, Cardiac Society of Australia and New Zealand Ralph Reader Prize

2016: Winner, John Funder Early Career Scientist Award

2015: Winner, The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologist/British Pharmacology Society Outstanding Investigator Award



Competitive Funding: Sole CI or CIA Grants

2020-2022: Australian Government National Health and Medical Research Council Ideas Grant: 

  • Exploiting Biased Agonists for Formyl Peptide Receptors as Pharmacotherapy for Pulmonary Hypertension

2020-2021: National Heart Foundation Vanguard Grant:

  • Formyl Peptide Receptor Agonists as Novel Therapy for Hypertension.

2020-2024: National Heart Foundation Future Leader Fellowship:

  • Therapeutic Targeting of Formyl Peptide Receptors to Treat Cardiovascular Disease.

2018: Diabetes Australia Research Program:

  • Discovering New Drugs to Treat Diabetes-induced Cardiovascular Complications.

2017-2018: Baker Early Career Scientist Small Grant:

  • Formyl Peptide Receptors (FPRs): A Novel Approach to Treat Hypertension.

2015: CASS (Contributing to Australian Scholarship and Science) Foundation:

  • Preventing Diabetes-induced Heart Failure with A Natural Anti-inflammatory Protein.



Competitive Funding: Other CI Grants

2019-2021: NHMRC Development Grant ($677K):

  • Prodrug Development of Biased N Alkylpyridazinones for the Acute Intravenous Treatment of Myocardial Ischaemia-Reperfusion Injury

2019-2020: JDRF RMS360 Leadership Program ($100K):

  • Regulatory T Cells and Kidney Disease Progression in Type 1 Diabetes.

2018-2019: The Inaugural Victorian Medical Acceleration Fund from Victorian Government ($97K):

  • Inhaled Formyl Peptide Receptor Agonists for Pulmonary Fibrosis.

2012-2015: The James and Elsie Borrowman Trust ($151,241 over 3 years).

  • Evaluating the Role of O-GlcNAcylation on The Pathogenesis of Abnormal Cardiac Function in Diabetes.